newsfilter
← Latest News
Business Wire·

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary